Survodutide
Boehringer Ingelheim / Zealand Pharma dual GLP-1 / glucagon receptor agonist (BI 456906). Strong Phase 2 obesity + MASH (liver) data. Phase 3 SYNCHRONIZE program ongoing across weight management, T2D, and liver disease indications.
Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.
What the research shows
Phase 2 obesity (n≈387, 46 weeks): ~18.7% mean body weight reduction at 4.8 mg weekly vs. ~2.0% placebo. Phase 2 MASH trial showed significant resolution of MASH without worsening fibrosis. Phase 3 SYNCHRONIZE program ongoing.
What's still experimental
Pre-approval — all use is investigational. Direct head-to-head vs. retatrutide and tirzepatide not yet available. Long-term cardiovascular and hepatic safety under evaluation.
Anecdotal / community reports
Limited grey-market presence so far. Most public discussion focuses on the dual-agonist mechanism vs. triple-agonist (Retatrutide) tradeoffs.
Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.
FDA approval status
Source: openFDA + DailyMed (NIH/NLM)Doses studied in research
Source: Published clinical trialWhat published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.
Highest tested arm — ~18.7% body weight reduction at 46 weeks
Open calculatorNotes from the source: Phase 3 SYNCHRONIZE program ongoing.
FDA enforcement & recalls
Live · openFDA Drug Enforcement APIMechanism & targets
ChEMBL · UniProt · Open TargetsMolecule (ChEMBL)
View on ChEMBL- CHEMBL1784agonistGlucagon-like peptide 1 receptor agonist
- CHEMBL1985agonistGlucagon receptor agonist
Live research
PubMed · ClinicalTrials.gov · Europe PMC · OpenAlexClinical trials (ClinicalTrials.gov)
- A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With ObesityACTIVE NOT RECRUITINGNCT06745284 · PHASE1 · n=64 · 2025-03-26
- A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like InjectorCOMPLETEDNCT07413913 · PHASE1 · n=56 · 2026-03-03
- A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightCOMPLETEDNCT06066528 · PHASE3 · n=755 · 2023-11-27
- A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or ObesityCOMPLETEDNCT06564441 · PHASE1 · n=34 · 2024-10-01
- A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or ObesityCOMPLETEDNCT06200467 · PHASE1 · n=110 · 2024-03-13
Europe PMC — 118 additional records
Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.
- Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversiesLempesis IG, Dalamaga M. · 2026Open access· cited 1×
- Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular ComorbiditiesPrikhodko VA, Okovityi SV. · 2026Open access
- Can an increase in abutment screw length enable biomechanical advantages for implants with increased crown height space?Keleş M, Güngör Erdoğan H, Yılmaz B., et al. · 2026Open access
- Overview of Diabetes Medications: Traditional and New-Generation Agents and Their Off-Label Use for Weight LossCastellana E, Budau PM, Chiappetta MR., et al. · 2026
Research volume (OpenAlex topic graph)
Human clinical evidence
Semantic Scholar · AI TLDRs · influence-rankedMost influential human studies
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.Journal article24 influential / 145 citedC. L. le Roux, Oren Steen, K. Lucas · The Lancet Diabetes and Endocrinology · 2024
TLDR All tested survodutide doses were tolerated, and dose-dependently reduced bodyweight.
- Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trialJournal articleOpen access12 influential / 91 citedMatthias Blüher, Julio Rosenstock, Josef Hoefler · Diabetologia · 2023
- The dual GCGR/GLP‐1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selectionJournal articleOpen access2 influential / 10 citedL. Thomas, Eric Martel, Wolfgang Rist · Diabetes, obesity and metabolism · 2024
TLDR The biomarker strategy that was applied to select survodutide from 19 dual glucagon receptor (GCGR)/ glucagon‐like peptide‐1 receptor (GLP‐1R) agonists for in‐depth pharmacological profiling, which led to the qualification of survodutide as the clinical development candidate is described.
- Survodutide, a new horizon in the treatment of obesity and Type 2 diabetes mellitus: A narrative reviewReviewOpen accessAbdelmoneim B. Yousif, Mohamed Fawzi Mudarres, Musaab Fahmi Yousef · Yemen Journal of Medicine · 2024
- Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial.ReviewOpen accessMikhail N. Kosiborod, E. Platz, Sean Wharton · JACC. Heart failure · 2024
TLDR SYNCHRONIZE-CVOT is the first trial that will determine the CV safety and efficacy of survodutide in people with obesity and increased CV risk, and the primary endpoint of SYNCHRONIZE-CVOT is time to first occurrence of the composite adjudicated endpoint of 5-point major adverse CV events.
Research funding & verification
NIH RePORTER · CrossRef DOI registryPublication landscape
CrossRef · DOI registry- National Natural Science Foundation of China30,998 works
- National Key Research and Development Program of China4,500 works
- Fundamental Research Funds for the Central Universities3,076 works
- China Postdoctoral Science Foundation1,960 works
- National Science Foundation1,386 works
- Natural Science Foundation of Shandong Province1,236 works
Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.
Preprints — cutting edge
bioRxiv · medRxiv · via Europe PMCKnown risks
GI side effects, theoretical concerns about glucagon-receptor activation impact on glucose homeostasis and lipid metabolism. Long-term safety under evaluation. Hepatic effects of the glucagon component being closely monitored.
Reported side effects
Nausea, vomiting, diarrhea, decreased appetite, fatigue. GI dose-titration required.
FDA adverse event reports (FAERS)
Updated quarterly by FDA- NZ1
- US1
Most-reported reactions
- Acute Kidney Injury2
- Acute Myocardial Infarction1
- Atrial Fibrillation1
- Upper Gastrointestinal Haemorrhage1
- Vomiting1
Counts from FDA Adverse Event Reporting System (FAERS). Voluntary reports — they show what was reported, not whether the drug caused the event. Many reports lack confirmation. FAERS docs
What requires medical supervision
Clinical-trial only. Patients should use FDA-approved options under prescriber care while awaiting approval.
Questions for your clinician
- Is the glucagon receptor activation relevant to my metabolic profile?
- Would a Phase 3 Survodutide trial be appropriate for me?
- How does this differ mechanistically from Retatrutide?